Key Differences Between MIT vs 7OH: Two Popular Kratom Alkaloids

Quick answer

Mitragynine (MIT) is the primary alkaloid in kratom leaf (roughly 60–70% of total alkaloids), while 7-hydroxymitragynine (7-OH) is a minor alkaloid present in the raw leaf at very low levels (typically under ~2%). The two differ by a single hydroxyl group, and research and regulators describe 7-OH as substantially more potent at opioid receptors — which is why MIT products are measured in grams and concentrated 7-OH tablets are measured in milligrams. This comparison is educational only and written for adults 21+.

What are MIT and 7-OH?

Both compounds come from Mitragyna speciosa (kratom), but they play very different roles:

• Mitragynine (MIT): the most abundant alkaloid in the leaf. It defines traditional kratom powder, tea, and capsules.
• 7-Hydroxymitragynine (7-OH): a minor leaf alkaloid. The body can also convert a small amount of MIT into 7-OH after consumption. In the raw leaf, 7-OH exists in trace amounts; concentrated 7-OH products isolate or produce much higher levels.

Chemical structure and properties

The two molecules are closely related. 7-OH is mitragynine with an added hydroxyl group at the 7 position — a small structural change with outsized consequences:

• Lipophilicity: the modification increases fat solubility, which is associated with more efficient access to the central nervous system.
• Receptor interaction: both interact with mu-opioid receptors as partial agonists, and MIT also interacts with several non-opioid receptor systems.
• Stability: 7-OH is less stable than MIT and more prone to degradation from heat, light, and oxygen, which affects formulation and storage.

Potency comparison: why it matters

This is the most important practical difference. Research estimates cited in the literature describe 7-OH as roughly 10–17× more potent than mitragynine at opioid receptors, and the FDA has stated that concentrated 7-OH is far more potent than morphine on a comparative basis. Because of this:

• MIT products are dosed in grams of leaf material.
• 7-OH products are dosed in milligrams of a concentrated compound.

The potency gap is also why concentrated 7-OH is treated as a distinct regulatory category from whole-leaf kratom (see the compliance note). Higher potency means a small amount represents a large difference — a reason the category emphasizes 21+ access and third-party testing.

How they work: mechanisms of action (in brief)

Both alkaloids act as partial agonists at mu-opioid receptors. MIT engages additional receptor systems, giving whole-leaf kratom a "full-spectrum" character. 7-OH's activity is more concentrated at the opioid receptor, consistent with its higher potency. We do not characterize subjective effects here; this is a structural and pharmacological comparison only.

Product types and availability

MIT dominates traditional kratom products, while 7-OH appears in the concentrated/enhanced segment. The related compound dihydro-7-hydroxymitragynine (MGM-15/DHM) is a further-modified derivative — see "What are MGM-15 tablets?" for that distinction.

Stability, storage, and formulation

Because 7-OH degrades more readily, concentrated products are typically formulated as tablets or sealed shots and benefit from cool, dark, airtight storage. MIT powder is comparatively more stable but still best kept dry and out of direct light. This stability difference is one reason 7-OH is rarely sold as loose powder at high concentration.

Tolerance and responsible-use context

Both alkaloids can lead to tolerance with repeated use, and available commentary suggests tolerance may build faster with the more potent compound. Commonly reported considerations for any kratom alkaloid include nausea, constipation, dizziness, and drowsiness. Because concentrated 7-OH is potent and its long-term profile is not established, the category stresses 21+ access, starting conservatively, and consulting a healthcare professional — especially for anyone taking other medications or with a history of substance use.

Choosing between MIT and 7-OH (informational framing)

Rather than a recommendation, here is how the two are generally positioned:

• MIT-dominant whole-leaf products are the traditional, lower-potency, gram-dosed category.
• Concentrated 7-OH products are the higher-potency, milligram-dosed category aimed at adults who already understand the distinction and their own tolerance.

Anyone comparing options should review third-party lab reports, confirm the product ships to their state, and remember that regulatory status is changing.

The future of MIT and 7-OH research

Research on kratom alkaloids is ongoing, and the regulatory picture is active: the FDA has moved to schedule 7-OH and several states restrict concentrated or synthetic forms. We do not summarize specific research outcomes here; readers interested in the science should consult primary sources and the American Kratom Association, and follow current FDA/DEA notices.

MIT vs. 7-OH: side-by-side quick reference

Which products contain which alkaloid

Traditional kratom powder, tea, and basic capsules are MIT-dominant. Concentrated 7-OH is what you find in 7-OH tablets, shots, and extracts, while the derivative dihydro-7-hydroxymitragynine appears in MGM-15 tablets. Knowing which alkaloid a product centers on tells you how it is dosed (grams vs. milligrams) and which regulatory category it falls under.

Common misconceptions

• "7-OH is just strong kratom." It is a distinct, far more potent alkaloid — not simply concentrated leaf.
• "Natural means milder." 7-OH occurs naturally but in trace amounts; concentrated products are a different proposition from whole leaf.
• "A bigger milligram number is better." Higher labeled strength is not a quality or value signal; for a potent compound it is a reason for more caution.

Responsible-use context, expanded

Because 7-OH is potent and its long-term profile is not established, the category emphasizes conservative first experiences, not combining with alcohol or other substances, secure storage away from minors, and a conversation with a healthcare professional — especially for anyone on other medications or with a history of substance use. Tolerance can build with either alkaloid and may build faster with the more potent one, which is why rotating products and taking breaks are commonly discussed.

Entity glossary (for clarity)

• Mitragynine (MIT): the primary, most abundant alkaloid in kratom leaf; defines traditional kratom products; dosed in grams.
• 7-Hydroxymitragynine (7-OH): a minor leaf alkaloid, far more potent at opioid receptors; the focus of concentrated 7-OH products; dosed in milligrams.
• Dihydro-7-hydroxymitragynine (DHM / MGM-15): a further-modified derivative of 7-OH, sold in tablet form.
• Alkaloid: a naturally occurring nitrogen-containing plant compound.
• Partial agonist: a molecule that activates a receptor less fully than a "full" agonist.
• Semisynthetic: derived from a natural source and then chemically modified in a lab.

How to apply the MIT vs. 7-OH distinction when shopping

The quickest practical test is the dosing unit: if a product is measured in grams, it is MIT-dominant whole-leaf material; if it is measured in milligrams, it is a concentrated 7-OH or derivative product. From there, check the certificate of analysis for the actual alkaloid content, confirm the product ships to your state, and remember that the concentrated category faces the most active regulatory change.

Key takeaways

• MIT is the major leaf alkaloid (grams); 7-OH is a minor, far more potent alkaloid (milligrams).
• They differ by a single hydroxyl group, with large consequences for potency and stability.
• 7-OH is less stable and degrades faster with heat, light, and oxygen.
• Concentrated 7-OH is treated as a distinct regulatory category from whole-leaf kratom.
• Compare using the COA and per-unit figures, not headline numbers.

The bottom line

MIT and 7-OH come from the same plant but behave very differently: mitragynine is the abundant, gram-dosed leaf alkaloid, while 7-hydroxymitragynine is a minor, far more potent, milligram-dosed compound that is less stable and more tightly regulated. The quickest way to tell which category a product belongs to is its dosing unit. Whichever you're comparing, rely on the certificate of analysis and per-unit figures rather than headline numbers, keep products away from minors, and remember that the concentrated 7-OH category is where regulation is changing fastest.

Frequently asked questions

Is 7-OH stronger than mitragynine?

Research and regulatory sources describe 7-OH as substantially more potent at opioid receptors than mitragynine. It is commonly cited as roughly 10–17 times more potent in certain experimental contexts, which helps explain why concentrated products are measured in milligrams rather than grams.

Is 7-OH natural?

7-OH occurs naturally in trace amounts in kratom leaves. Concentrated 7-OH products may isolate the compound or produce it semisynthetically from mitragynine.

Will both show up on a kratom drug test?

A kratom-specific LC-MS/MS panel can detect both mitragynine and 7-OH when the test is designed to identify them. Standard 5-panel drug tests do not specifically target either compound. See our drug-test guide.

Which is better for beginners?

We don't make effect-based recommendations. In general, traditional whole-leaf kratom products are typically mitragynine-dominant, while concentrated 7-OH products contain a more potent opioid-receptor-active compound. Concentrated products carry greater safety concerns and should not be assumed to be safer because they are measured in milligrams.

Does the body turn MIT into 7-OH?

Yes. The body can metabolize some mitragynine into 7-OH after consumption. However, this metabolic process differs from consuming a concentrated 7-OH product directly.

Important notice

Educational and informational only; not medical or legal advice and not a claim about safety or effects. For adults 21+. 7-hydroxymitragynine is not FDA-approved for food, supplement, or drug use, and regulatory status varies by jurisdiction and continues to change. Consult applicable law and a qualified professional.